Can Immune Checkpoint Modulation Redefine Ocular Immunotherapy? Emerging Mechanisms, Challenges, and Translational...

Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and their application is now expanding to various conditions, including prevalent medical issues such as uveal melanoma, autoimmune uveitis, and surface squamous neoplasms. The unique immunological challenges in these cases arise from the immune-privileged nature of the eye, which employs immune evasion mechanisms that often lead to an advanced disease at diagnosis. Recent breakthroughs in immune checkpoints have identified critical regulatory molecules, such as PD-1, CTLA-4, TIM-3, LAG-3, and CEACAM1, which are pivotal in modulating ocular immune responses. The use of novel immunotherapeutic strategies to block these pathways presents new opportunities to treat ocular and inflammatory eye disorders. T-cell exhaustion (Tex) is a significant hurdle in ocular immunotherapy that results in immune dysfunction because of prolonged antigen exposure. Strategies to counteract Tex, including combination therapies that pair PD-1 inhibitors with co-stimulatory agonists such as OX40 and CD137, have shown promise in preclinical murine models. Additionally, dual blockade targeting TIM-3 alongside PD-1 has been found to enhance T-cell responses. An integrated approach targeting multiple pathways may yield improved therapeutic outcomes in eye diseases characterized by immune dysregulation. However, several challenges remain in optimizing immune checkpoint therapies for ocular conditions. Future research should prioritize dual objectives: (1) developing IL-10/TGF-β-promoting therapies to mitigate immune-related adverse events (e.g., retinal vasculitis) and (2) validating LAG-3 + tumor-infiltrating lymphocytes as biomarkers for predicting immune checkpoint inhibitor response in uveal melanoma. It is essential to explore effective combinations of checkpoint inhibitors, determine the optimal timing for their use, and establish better criteria for patient selection. As research on immune checkpoint therapies progresses, they have the potential to transform the management of ocular diseases, offering innovative treatment options for patients who previously had limited choices.